Merck & Co., Inc., Rahway, NJ, USA.
Evidera, Seattle, WA, USA.
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099737. doi: 10.1177/17534666221099737.
The Leicester Cough Questionnaire (LCQ), a cough-specific quality-of-life measure, evaluates the impact of cough across physical, psychological, and social domains in patients with chronic cough (CC). This study assessed the psychometric properties of the LCQ.
Data from a phase IIb, randomized controlled trial of the P2X3-receptor antagonist gefapixant were analyzed (NCT02612610). Subjective [Cough Severity Diary, cough severity visual analogue scale, and patient global impression of change (PGIC)] and objective (awake and 24-h cough frequency) data were used to validate the LCQ for use in patients with refractory or unexplained CC (RCC and UCC, respectively). Psychometric analyses included confirmatory factor analyses, internal consistency and test-retest reliability, validity, responsiveness, and estimated within-patient thresholds for clinically meaningful change.
Model-fit values for the proposed three-factor LCQ domains and most individual items were acceptable. Analyses suggest that a mean improvement ranging from 1.3 to 2.3 points for the LCQ total and ⩾0.8, ⩾0.9, and ⩾0.8 points for physical, psychological, and social domain scores, respectively, had the best sensitivity and/or specificity for predicting patient ratings of improvement on the PGIC.
The LCQ is a valid and reliable measure to evaluate cough-specific quality of life and is a fit-for-purpose measure for use in patients with RCC or UCC. Although a single threshold for defining clinically meaningful change depends on the context of use, the results can help guide both treatment decisions and drug development. Therefore, clinicians may consider a ⩾1.3-point increase in the LCQ total score as clinically meaningful.
莱斯特咳嗽问卷(LCQ)是一种咳嗽特异性生活质量量表,评估了慢性咳嗽(CC)患者咳嗽对身体、心理和社会领域的影响。本研究评估了 LCQ 的心理测量特性。
对 P2X3 受体拮抗剂 gefapixant 的 IIb 期随机对照试验的数据进行了分析(NCT02612610)。使用主观[咳嗽严重程度日记、咳嗽严重程度视觉模拟量表和患者整体印象变化(PGIC)]和客观(清醒和 24 小时咳嗽频率)数据来验证 LCQ 在难治性或不明原因 CC(RCC 和 UCC)患者中的适用性。心理测量分析包括验证性因子分析、内部一致性和重测信度、有效性、反应性以及估计患者个体临床有意义变化的阈值。
提出的三个 LCQ 领域和大多数单个项目的模型拟合值是可以接受的。分析表明,LCQ 总分的平均改善范围为 1.3 至 2.3 点,身体、心理和社会领域的得分分别为 0.8、0.9 和 0.8 点以上,对预测患者对 PGIC 的改善评分具有最佳的敏感性和/或特异性。
LCQ 是一种有效的、可靠的评估咳嗽特异性生活质量的工具,适用于 RCC 或 UCC 患者。虽然定义临床有意义变化的单一阈值取决于使用的背景,但结果可以帮助指导治疗决策和药物开发。因此,临床医生可以考虑将 LCQ 总分增加 1.3 点作为临床有意义的变化。